We have demonstrated that USP22 depletion inhibits hepatocellular carcinoma cell proliferation and promotes the sensitivity of hepatocellular carcinoma cells to Sorafenib‐induced ferroptosis by in vitro assays. Here, USP22 is linked to hepatocellular carcinoma.